Anika Therapeutics, Inc.
Financials
Valuation Metrics
Anika Therapeutics, Inc.'s Market Cap is $277M. At end of 2025 it was $137M. Ranked #2962 of 3,121 in US market (top 95%), #1341 of 1,463 on NASDAQ (top 92%), #188 of 205 in Health Care Equipment & Services (top 92%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $277M | US#2,962/3,121 Sec#188/205 |
| Revenue | $121M | US#2,668/3,121 Sec#178/205 |
| Net Income | $-4M | US—/3,121 Sec—/205 |
| Total Assets | $183M | US#3,009/3,121 Sec#189/205 |
| Net Assets | $137M | US#2,767/3,121 Sec#171/205 |
| Employees | 235 | US#2,466/3,121 Sec#168/205 |
| Value | ||
| P/B | 2.02x | US#1,271/3,121 Sec#61/205 |
| P/S | 2.29x | US#1,428/3,121 Sec#96/205 |
| EV/EBITDA | 96.35x | US#2,434/3,121 Sec#135/205 |
| FCF Yield | 0.20% | US#2,262/3,121 Sec#139/205 |
| Profitability | ||
| ROE | -2.76% | US#2,208/3,121 Sec#120/205 |
| ROA | -2.06% | US#2,387/3,121 Sec#129/205 |
| Op. Margin | -4.24% | US#2,466/3,121 Sec#144/205 |
| Revenue Growth | 5.33% | US#1,771/3,121 Sec#129/205 |
| Financial Health | ||
| Debt Ratio | 33.65% | US#382/3,121 Sec#38/205 |
| Total Debt | $23M | US#2,732/3,121 Sec#169/205 |
| FCF | $562000.00 | US#2,288/3,121 Sec#141/205 |
| Cash | $38M | US#2,688/3,121 Sec#174/205 |
| Current Ratio | 4.48x | US#535/3,121 Sec#49/205 |
| Net Debt/EBITDA | -5.56x | US#65/3,121 Sec#7/205 |
| Performance | ||
| 1Y Return | 132.77% | US#116/3,121 Sec#12/205 |
| 1M Return | -2.12% | US#1,306/3,121 Sec#113/205 |
| From 52W High | -9.05% | US#563/3,121 Sec#57/205 |
| 1Y MDD | -22.56% | US#892/3,121 Sec#21/205 |
| Trading | ||
| Volume | 68,126 shares | US#3,062/3,121 Sec#204/205 |
| Trading Value | $1M | US#3,027/3,121 Sec#195/205 |
| Per Share | ||
| EPS | $-0.28 | US—/3,121 Sec—/205 |
| BPS | $10.32 | US#1,827/3,121 Sec#104/205 |
Company Info
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.